




NEW YORK STATE BAR ASSOCIATION
Serving the legal profession and the community since 1876



Food, Drug and Cosmetic Law Section Annual Meeting – January 25, 2018

Embracing the Continuum of Risk: New FDA Policies in the Aftermath of the Deeming Rule

Anne Pierson Allen, Esq.
King & Spalding
New York, NY

Christina Young, PhD
King & Spalding
Washington, D.C.

KING & SPALDING

FDA's Comprehensive Policy Announcement

- On July 28, 2017, Commissioner Gottlieb announced FDA's multi-year comprehensive plan for tobacco and nicotine regulation
- Plan includes:
 - Delaying current regulatory deadlines
 - Issuance of final rules on tobacco product applications, final guidance, and product standards
 - Issuance of ANPRMs regarding: (1) nicotine in cigarettes, (2) flavors; and (3) premium cigars
 - Reassessment of current policies on provisional SE reports

Additional Priorities

- Director Mitch Zeller of the Center for Tobacco Products gave the keynote speech at FDLI's annual tobacco products regulation conference
- He identified a need for a sustained national dialogue to:
 - Correct common misperceptions
 - Address nicotine's role in continuum of risk
 - Address nicotine and youth
 - Address nicotine and adult populations
 - Identify vulnerable populations

Stakeholder Response

- Stakeholder analysis of the plan has focused on:
 - Feasibility of the plan
 - Implementation process and timeline
 - Gaps in the comprehensive plan
 - Identifying “common ground” between industry, public health community, and FDA
 - Scientific research efforts
 - Necessary improvements in current regulatory regime



Key Components of FDA's Plan

Delay of Current Regulatory Deadlines

- Under the Final Deeming Rule, FDA set deadlines for submission of premarket review applications for newly-regulated tobacco products that were on the market as of August 8, 2016
- FDA extended the deadline to submit tobacco product applications for newly deemed tobacco products
 - Combustible products: August 8, 2021
 - Non-combustible products: August 8, 2022
- **Can continue to market** these products during this period and while the application is pending with FDA
 - Only applies to products on market as of Aug. 8, 2016

Issuance of Final Rules

- With additional time to submit applications, FDA intends to initiate and complete rulemaking for:
 - Premarket Tobacco Product Applications
 - Substantial Equivalence Applications
 - Modified Risk Tobacco Product Applications
 - Tobacco Product Manufacturing Practices
- In the near-term, FDA intends to finalize the draft guidance, Premarket Tobacco Product Applications for Electronic Nicotine Delivery Systems (ENDS)

Stakeholder Concerns

- **Feasibility** – can FDA finalize these rules in five years, with sufficient time for industry to implement in advance of submitting their applications
- **Attainable Standards** – will these final rules set forth reasonable, predictable, and practical processes to submit applications
 - Altria’s PMTA/MRTPA application is roughly 2.5 million pages
- **Marketing Freeze** – this extension only applies to products on the market as of August 8, 2016, limiting further innovation and improvement upon these products

Stakeholder Engagement

- FDA intends to issue ANPRMs on the following:
 - Lowering nicotine in cigarettes to non-addictive or minimally addictive levels
 - Role of flavors (including menthol) in attracting youth and helping smokers switch to potentially less harmful forms of nicotine delivery
 - Patterns of use and resulting public health impacts from premium cigars
- As of December 2017, ANPRMs for premium cigars and “kid-appealing flavors” are under OMB review

Product Standards

- Utilizing FDA's product standard authority, FDA intends to lower nicotine in cigarettes to non-addictive or minimally addictive levels
- In January 2017, FDA issued proposed product standard for NNN in smokeless tobacco products
 - Received over 7,700 comments on the proposed rule

Stakeholder Concerns

- **Lowering Nicotine in Cigarettes:**
 - Creation of an illicit market
 - Overcompensation
 - Unintended consequences
- **Lowering NNN in Smokeless Tobacco Products:**
 - Feasibility: For NNN proposed product standard, the maximum permitted would be significantly lower than the majority of products on the market today

Stakeholder Concerns (cont'd)

- **Flavors:**
 - Issue of appeal to children versus role in converting adults from combustible to non-combustible tobacco products
- **Premium Cigars:**
 - Would require amending the Final Deeming Rule
 - Impact on the market without a change to the existing rule

Reassessment of Current Policies

- Commissioner Gottlieb asked FDA's Center for Tobacco Products to analyze the Agency's current plan to review all provisional SE reports and assess the following:
 - Effective use of agency resources?
 - More appropriate approach to provisional SE reports?
 - Whether greater clarity could be provided to the market?

Stakeholder Concerns

- Provisional SE reports have been pending with FDA since March 22, 2011
 - Over 3,500 submitted by March 22, 2011, but FDA has resolved only 28% of these provisional SE reports
- Effective use of resources – significant resources involved in undertaking review of these products
- Cost and time involved in responding to deficiencies
- FDA is constantly moving the goalpost



Questions or Comments?

Thank you!